---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-22-000037"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T15:51:58.165112+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVS Q3 GAAP loss $(2.60) on opioid/LTC charges; adj. EPS $2.09 beat; raises full-year adj. guidance

## Summary
- Total revenues $81.2B (+10.0% YoY); GAAP diluted loss per share $(2.60) vs $1.20 EPS prior year.
- GAAP results include $5.2B pre-tax opioid litigation charge and $2.5B pre-tax loss on LTC business held for sale.
- Adjusted EPS of $2.09 vs $1.97 prior year; full-year adj. EPS guidance raised to $8.55-$8.65 from $8.40-$8.60.
- Full-year GAAP EPS guidance lowered to $3.12-$3.22 from $7.23-$7.43 due to the charges.
- Agreed to acquire Signify Health for $30.50/share (~$8B total); repaid $2.6B debt and paid $726M dividends in Q3.

## SEC filing metadata
- accession: 0000064803-22-000037
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/0000064803-22-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/cvs-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-22-000037
- JSON: https://secwatch.observer/filing/0000064803-22-000037.json
- Plain text: https://secwatch.observer/filing/0000064803-22-000037.txt

## Key facts
- Earnings Releases
  CVS HEALTH Corp reported three months ended September 30, 2022 results: revenue $81.2 billion, EPS $(2.60). Guidance raised.
  - Period: three months ended September 30, 2022
  - Revenue: $81.2 billion
  - EPS: $(2.60)
  - Guidance: raised
  - Result: reported results
  source text: Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2022. THIRD QUARTER RESULTS KEY FINANCIAL DATA • Total revenues increased to $81.2 billion, up 10.0% compared to prior year • GAAP loss per share of $(2.60), inclusive of $5.2 billion pre-tax opioid litigation charges and a $2.5 billion pre-tax loss on assets held for
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/0000064803-22-000037-index.htm
- Earnings Releases
  CVS HEALTH Corp reported 2022 (year-to-date) results: revenue $238.6 billion, EPS $1.40. Guidance raised.
  - Period: 2022 (year-to-date)
  - Revenue: $238.6 billion
  - EPS: $1.40
  - Guidance: raised
  - Result: reported results
  source text: Total revenues increased to $238.6 billion, up 10.7% compared to prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000006480322000037/0000064803-22-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.